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Anticoagulation is fundamental in the management of patients with atrial fibrillation
(AF). The study aims to provide a comparative review of the major phase III random-
ized clinical trials (RCTs) and real-world data (RWD) from reliable, high-grade Phase
IV studies that assess the efficacy and safety of non-vitamin K antagonist oral anticoa-
gulants (NOACs) vs. vitamin K antagonists (VKAs). Observational studies based on na-
tionwide or health insurance database records on the use of NOACs vs. VKAs in
patients with AF were included. We performed a comparison of the efficacy and
safety characteristics associated with NOACs vs. VKAs in RCTs and RWD. Although RCTs
provide strong support for evidence-based practice, RWD may be used to reflect the
broader picture of various clinical settings, provide supplementary insight and fulfil
knowledge gaps. Both study types confirmed the safety and efficacy of NOACs in pre-
venting stroke and thromboembolism in patients with AF. In comparison to VKAs,
NOACs were associated with reduced risk of ischaemic events and lower rates of ad-
verse events such as major bleeding or intracranial haemorrhage. Administration of
NOACs might be associated with increased risk of dose-related gastrointestinal bleed-
ing and myocardial ischaemic events, especially in the early treatment period after
switching from VKAs. Special care should be taken in challenging clinical situations
like severe renal or hepatic impairment when the treatment regimen needs to be
considered individually. Randomized clinical trial and RWD studies are complementary
and present comparable findings, affirming that NOACs are safe and effective for anti-
coagulation of patients with AF in daily clinical practice.
Introduction
Atrial fibrillation (AF) is the most prevalent sustained
cardiac arrhythmia and a major cause of cerebrovascular-
related mortality and morbidity.1,2 Hence, stroke
prevention is an important focus in the management of AF.3
Vitamin K antagonists (VKAs, mainly warfarin), have been
the treatment of choice to prevent systemic thromboem-
bolism in AF prior to the discovery of non-vitamin K antago-
nist oral anticoagulants (NOACs), also known as direct oral
anticoagulants.4–6 Although both groups of drugs are effec-
tive at reducing thrombo-embolic risk there is a suggestion
that NOACs may be superior with regards to ease of use,
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wider therapeutic range, and less major bleeding.7–9 As
these drugs have been widely used for several years; there
is emerging evidence regarding their safety profile from
various registers.
In general, randomized control trials (RCTs) are accepted
as the gold standard to assess the effectiveness and safety
of therapeutic interventions. They often provide robust
and high-quality evidence, from which guideline recom-
mendations are derived. Nonetheless, the selection of
patients in RCTs are based upon their strict inclusion and
exclusion criteria and study setting. As a result, these trials
may not be applicable to many patients with similar condi-
tions who are encountered in daily clinical practice. In this
regard, real-world data (RWD) provide a more accurate
representation of the study population in the clinical set-
ting. As a result, the popularity of real-world studies, as
well as their importance in the world of science, have in-
creased significantly over the last decade.10 Despite this,
there are several limitations with RWD. For example, they
are reliant on information from various sources such as
electronic health records, patient or disease registries,
and insurance databases. Therefore, the quality of data
may be variable which may result in a disparity between
the findings from RCTs and real-world studies.11,12
Consequently, it is important to integrate and analyse evi-
dence from both sources, as RWD verifies and complements
the data obtained from RCTs. When their findings are
consistent, the reliability of the information provided
increases significantly.13
Since the introduction of NOACs, several research stud-
ies, either phase III clinical trials or in the real-world set-
ting, have been conducted on their safety and therapeutic
effects compared to VKAs. These studies differ consider-
ably in terms ofmethodology, research group, and results.
The purpose of this study is to perform a comparative re-
view of the data from major phase III clinical trials and
real-world evidence from reliable, high-grade Phase IV
studies that assess the efficacy and safety of NOACs vs.
VKAs.
Methodology
We searched PubMed for observational studies based on na-
tionwide or health insurance database records relating to
the implementation of NOACs vs. VKAs in patients with AF.
We conducted a comparison of efficacy and safety out-
comes associated with the use of NOACs or warfarin from
the following phase III, randomized trials of patients with
AF: RE-LY,8 ROCKET-AF,14 ARISTOTLE,15 ENGAGE-TIMI 48,16
and RWD or Phase IV evidence with regard to the risk of
stroke or systemic embolism, ischaemic stroke, myocardial
infarction, major haemorrhage, intracranial haemorrhage,
gastrointestinal haemorrhage, and all-cause death
(Table 1).
Dabigatran vs. warfarin
In light of the RE-LY study, both efficacy and safety of dabi-
gatran were dose-dependent.8 Undeniably, administration
of high-dose dabigatran (150mg) compared to warfarin
therapy was associated with a significant reduction in the
rate of stroke or systemic embolism [relative risk (RR)
0.66, 95% confidence interval (CI) 0.53–0.82; P< 0.001),
with similar overall rate of bleeding, including major hae-
morrhage (RR 0.93, 95% CI 0.81–1.07; P¼ 0.31). However,
the rate of gastrointestinal bleeding with high-dose dabiga-
tran was higher compared to warfarin therapy (RR 1.50,
95% CI 1.19–1.89; P< 0.001) (Table 1).8 In contrast, dabiga-
tran at the dose of 110mg was non-inferior compared to
warfarin therapy in the rate of stroke or systemic embolism
(RR 0.91, 95% CI 0.74–1.11; P¼ 0.34), with a significantly
lower rate of bleeding, including major haemorrhage (RR
0.80, 95% CI 0.69–0.93; P¼ 0.003) (Table 2).8 Other impor-
tant findings in the RE-LY study were related to a numeri-
cally but non-significant increase in myocardial infarction
with high-dose dabigatran, but no statistical difference in
all-cause death (Table 2).
In support of the results above, the available RWD found
dabigatran to have similar efficacy compared to warfarin
but with a better safety profile.13 Dabigatran use com-
pared to warfarin was associated with lower risk of intra-
cranial haemorrhage [hazard ratio (HR) 0.42, 95% CI 0.37–
0.49; P< 0.001],17–28 and all-cause death (HR 0.63, 95% CI
0.52–0.76; P< 0.001).19,20,22,25,29,30 There was no sugges-
tion of a higher risk of myocardial infarction with dabiga-
tran use in five studies utilizing real-world
databases.18,19,25,31,32 Both RCTs and RWD were broadly
consistent with comparable effects of dabigatran and war-
farin in reducing the risk of stroke and systemic embo-
lism24,31,33–36 and increased risk of gastrointestinal
bleeding with high-dose dabigatran (Table 2).8,13,17–22,25–28
The inconsistencies observed between the RCTand RWD
are likely multifactorial.
Most of the RCTs aremulticentre studies which were con-
ducted with a predominantly international western
European or American population. There was often minor
participation from those in other regions. Although RWD
studies are also frequently performed on large populations,
they usually based on nationwide cohorts, which may or
may not be ethnically diverse, and might reflect the dis-
crepancies resulting from the specific population
characteristics.
Therefore, genetic and environmental factors may ac-
count for some of the differences seen. For instance, a
real-world study in an Asian cohort showed no significant
disparity in the risk of gastrointestinal bleeding or myocar-
dial infarction between those on dabigatran and warfa-
rin.19 Another reason for the inconsistencies may be
related to inappropriate use of dosing regimens. It was pre-
viously reported that there was a frequent prescription of
low-dose dabigatran among Asian patients in the real
world, due to false assumptions associated with lower body
size in this population.
Real-world data studies also shed light on the possibility
of increased risk of gastrointestinal bleeding and myocar-
dial infarction in patients receiving dabigatran vs. warfa-
rin, while identifying that a switch to NOACs from VKA was
associated with an initial high-risk period. This may partly
be explained by the need for drug saturation and weaker
attenuation of thrombin generation early on with the use
of dabigatran.18,25,27
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Rivaroxaban vs. warfarin
Results from the ROCKET-AF study and RWD18,26,33,37
were comparable with regards to the influence on the
risk of stroke or systemic embolism, ROCKET-AF
reported a lower risk of stroke or systemic embolism
with rivaroxaban compared to warfarin using an on-
treatment analysis (HR 0.79, 95% CI 0.65–0.95; P¼ 0.01
for superiority) (Table 2). However, the risk of stroke or
systemic embolism was non-significant with a conven-
tional intention-to-treat analysis.14 Based on a system-
atic review and meta-analysis of 28 real-world studies,
no significant difference was found between rivaroxa-
ban and warfarin in terms of ischaemic stroke or sys-
temic embolism risk (HR 0.73, 95% CI 0.52–1.04;
P¼ 0.13).13 Despite the lack of statistical difference
between rivaroxaban and warfarin for the outcome of
major haemorrhage21,26,29,31,33,35,37,38 either in the
RCT (HR 1.04, 95% CI 0.90–1.20; P ¼ 0.58) or RWD (HR
1.00, 95% CI 0.92–1.08; P¼ 0.92), both the RCTand RWD
concur that rivaroxaban had a significant advantage
over warfarin in lowering the risk of intracranial hae-
morrhage (RCT: HR 0.67, 95% CI 0.47–0.93;
P¼ 0.02).13,14,18,21,24,26,33,37,39 Both types of studies
consistently found no significant difference between
rivaroxaban and warfarin therapy in the risk of myocar-
dial infarction18,31 and all-cause death29,33 (Table 2).
Moreover, the use of rivaroxaban was associated with a
higher risk of gastrointestinal haemorrhage compared
to warfarin18,26,33,37 (Table 3).
Apixaban vs. warfarin
Most studies on apixaban were positive with a favourable
risk–benefit ratio.13,24,26, Moreover, in the RWD, the ana-
lysed outcomes (stroke, all-cause mortality, major hae-
morrhage, intracranial, and gastrointestinal bleeding
rates), were even more beneficial than in the RCT.13,15
In the ARISTOTLE study, compared to warfarin, apixaban
significantly reduced the risk of stroke or systemic em-
bolism (HR 0.79, 95% CI 0.66–0.95; P¼ 0.01) and also de-
creased the risk of bleeding, including major and
intracranial haemorrhage (HR 0.69, 95% CI 0.60–0.80;
P< 0.001; HR 0.42, 95% CI 0.30–0.58; P< 0.001, respec-
tively) (Table 3). There was no difference between apix-
aban and warfarin in the risk of gastrointestinal bleeding
in the ARISTOTLE trial (HR 0.89, 95% CI 0.70–1.15;
P¼ 0.37), while the risk of GI bleeding was significantly
lower with apixaban in the RWD (HR 0.63, 95% CI 0.42–
0.95; P¼ 0.03).21,29 Similar findings that were reported
in the RCT for other parameters were observed in the
RWD, which supports and confirms the superiority of
apixaban over warfarin (Table 4).21,24,26,29,38,39 Another
important finding in the RCT, which was consistent in
real-world studies was the significant reduction in all-
cause death with apixaban compared to warfarin (RCT:
HR 0.89, 95% CI 0.80–0.998; P¼ 0.047; RWD: HR 0.65,
95% CI 0.56–0.75; P< 0.00001).15,29 Additionally, apixa-
ban therapy in ARISTOTLE was associated with a lower
rate of discontinuation compared to warfarin (25.3% vs.
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27.5%, P< 0.001, respectively).15 Unlike RCTs, discon-
tinuation rates are rarely analysed in the RWD. From the
limited data available, a study on 51 000 patients with
AF showed no relevant differences in discontinuation
rates between the use of apixaban and warfarin.40
However, a separate real-world study demonstrated
higher adherence to apixaban compared to warfarin in
the long-term.41
Edoxaban vs. warfarin
There are more real-world or Phase IV evidence on the
effects of edoxaban compared to other NOACs. There are
two approved edoxaban dose regimens, based on patients
individual characteristic: high-dose edoxaban regimen
(60mg) and reduced to 30mg (low-dose edoxaban regi-
men) used in patients when estimated creatinine clearance
Table 2. Dabigatran in comparison to VKA
Dose (mg)
Event
Real-world data studies13 RE-LY trial8
Dabigatran dose adjusted Dabigatran 110 mg Dabigatran 150 mg
Stroke or
systemic embolism
No statistical difference No statistical difference Lower rate
(HR 0.93, 95% CI 0.77–1.14;
P ¼ 0.21)
(RR 0.91,95% CI 0.74–1.11 P ¼ 0.34) (RR 0.66, 95% CI 0.53–0.82;
P < 0.001
Ischaemic
stroke
No statistical difference No statistical difference Lower rate
(HR 0.96, 95% CI 0.80–1.16;
P ¼ 0.69)
(RR 1.11, 95% CI 0.89–1.40;
P ¼ 0.35)
(RR 0.76, 95% CI 0.60–0.98;
P ¼ 0.03)
Myocardial
infarction
No statistical difference Higher rate Higher rate
(HR 0.96, 95% CI 0.77–1.21;
P ¼ 0.74)
(RR 1.35, 95% CI 0.98–1.87;
P ¼ 0.07)
(RR 1.38, 95% CI 1.00–1.91;
P ¼ 0.048)
All-cause
mortality
Lower risk No statistical difference No statistical difference
(HR 0.63, 95% CI 0.52–0.76;
P < 0.001)
(RR 0.91, 95% CI 0.80–1.03;
P ¼ 0.13)
(RR 0.88, 95% CI 0.77–1.00;
P ¼ 0.051)
Major
haemorrhage
No statistical difference Lower rate No statistical difference
(HR 0.83, 95% CI 0.65–1.05;
P ¼ 0.12)
(RR 0.80, 95% CI 0.69–0.93;
P ¼ 0.003)
(RR 0.93, 95% C; 0.81–1.07;
P ¼ 0.31)
Intracranial
haemorrhage
Lower risk Lower rate Lower rate
(HR 0.42, 95% CI 0.37–0.49;
P < 0.001)
(RR 0.31, 95% CI 0.20–0.47;
P < 0.001)
(RR 0.40, 95% CI 0.27–0.60;
P < 0.001)
Gastrointestinal
haemorrhage
Higher risk No statistical difference Higher rate
(HR 1.20, 95% CI 1.06–1.36;
P ¼ 0.003)
(RR 1.10, 95% CI 0.86–1.41;
P ¼ 0.43)
(RR 1.50, 95% CI 1.19–1.89;
P < 0.001)
RE-LY, The Randomized Evaluation of Long-Term Anticoagulation Therapy.
Table 3. Rivaroxaban in comparison to VKA
Dose (mg)
Event
Real-world data studies13 ROCKETAF trial14
Rivaroxaban dose adjusted Rivaroxaban 20 mg
Stroke or systemic embolism No statistical difference Lower rate
(HR 0.87, 95% CI 0.71–1.07; P ¼ 0.08) (HR 0.79, 95% CI 0.65–0.95; P ¼ 0.02 for superiority)
Ischaemic stroke No statistical difference No statistical difference
(HR 0.89, 95% CI 0.76–1.04; P ¼ 0.13) (HR 0.94, 95% CI 0.75–1.17; P ¼ 0.581)
Myocardial infarction No statistical difference No statistical difference
(HR 1.02, 95% CI 0.54–1.89; P ¼ 0.96) (HR 0.81, 95% CI 0.63–1.06; P ¼ 0.121)
Death No statistical difference No statistical difference
(HR 0.67, 95% CI 0.35–1.30; P ¼ 0.24) (HR 0.85, 95% CI 0.70–1.02; P ¼ 0.073)
Major haemorrhage No statistical difference No statistical difference
(HR 1.00, 95% CI 0.92–1.08; P ¼ 0.92) (HR 1.04, 95% CI 0.90–1.20; P ¼ 0.58)
Intracranial haemorrhage Lower rate Lower rate
(HR 0.64, 95% CI 0.47–0.86; P ¼ 0.004) (HR 0.67, 95% CI; 0.47–0.93; P ¼ 0.02)
Gastrointestinal haemorrhage Higher rate Higher rate
(HR 1.24, 95% CI 1.08–1.41; P ¼ 0.002) (HR 1.47, P < 0.001)
ROCKET AF, The Rivaroxaban Once Daily Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism
Trial in Atrial Fibrillation.
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(CrCl) of 30–50mL/min, a body weight of 60 kg, or the con-
comitant use of specific PgP inhibitors.
In general, the RWD are consistent with the ENGAGE AF-
TIMI 48 study, supporting the better safety profile of edoxa-
ban compared to warfarin. In the RCT, both edoxaban
treatment regimens (low- or high-dose) were non-inferior
in comparison to warfarin for stroke prevention, but the
study placed a greater emphasis on the higher efficiency in
stroke prevention with use of the higher, recommended
dose. Moreover, both doses of edoxaban were associated
with reduced adverse events includingmajor bleeding, car-
diovascular death, and composite outcome (defined as
stroke/systemic embolism or cardiovascular death) com-
pared to warfarin.42 The aforementioned results were
broadly consistent with those from RWD studies but also in-
dicated the efficacy of the lower edoxaban dose in stroke
and systemic embolism prevention and safety in terms of
reducing bleeding adverse events (Table 5). Edoxaban was
reported to be superior compared to warfarin in terms of
efficacy and safety in real-world studies conducted in an
Asian population.43,44 In comparison to warfarin, the rate
of ischaemic stroke in isolation in the RCTwas higher with
low-dose edoxaban (HR 1.41, 95% CI 1.19–1.67; P< 0.001)
but similar with high-dose edoxaban (HR 1.00, 95% CI 0.83–
1.19; P¼ 0.97).42 The reduced efficacy of low-dose edoxa-
ban was not observed in real-world studies.43,44 There
were further discrepancies shown between the results
from the RCTand RWD for edoxaban. For example, the rate
of myocardial infarction was lower for both low- and high-
dose edoxaban compared to warfarin in the RWD (HR 0.58,
95% CI 0.35–0.98 and HR 0.34, 95% CI 0.15–0.81, respec-
tively). Meanwhile, the RCTreports no benefit of edoxaban
in this regard (Table 4).42–44 Furthermore, the risk of gas-
trointestinal haemorrhage was increased with high-dose
edoxaban compared to warfarin in the RCT (HR 1.23, 95%
CI 1.02–1.50; P¼ 0.03), whilst this risk was found to be
lower with both low- and high-dose edoxaban in the
RWD.43,44 In terms of the risk of major bleeding,
intracranial haemorrhage, and death, both RCT and RWD
appear broadly similar with reduced risk in edoxaban com-
pared to warfarin therapy (Table 5).42–44
Non-vitamin K antagonist oral anticoagulants
as a group
When considering the individual NOACs as a group, despite
minor differences in the effects of each drug, mainly in
terms of gastrointestinal haemorrhage andmajor bleeding,
they are all as effective as warfarin in preventing stroke or
systemic embolism but with a lower risk of intracranial
bleeding. This was a consistent finding observed through-
out all the major studies, in both the RCTs and RWD.
Overall, NOACs were characterized by a favourable risk–
benefit ratio due to a better safety profile compared to
warfarin. An additional advantage of NOACs over warfarin
based on comprehensive comparisons of real-world out-
comes in patients with AF was the substantial reduction in
healthcare costs.45 Moreover, expenditure for all-cause
hospitalization and outpatient medical care were lower for
NOACs compared with warfarin.46 In terms of practicality
and patient satisfaction, a further advantage of NOACs was
related to better patients adherence due to ease of use
with no need for frequent laboratory monitoring or dose
adjustments. Furthermore, NOACs were proven to have
fewer interactions with food and other medications com-
pared to warfarin.47
Several analyses have assessed whether the superiority
of NOACs over warfarin was dependent on anticoagulation
control with warfarin therapy (i.e. time-in-therapeutic
range).48,49 Nonetheless, well-managed warfarin therapy
was proven to be efficient and associated with low risk of
adverse events,48 NOAC medication seems to have better
adherence, and therefore, in general, are associated with
better outcomes.49 Hence, it appears that NOACs may be a
better option for patients with difficulties in maintaining
adequate anticoagulation control with warfarin.50–52 Also
Table 4. Apixaban in comparison to VKA
Dose (mg)
Event
Real-world data studies13 ARISTOTLE trial15
Apixaban dose adjusted Apixaban 5 mg
Stroke or systemic embolism Lower rate Lower rate
(HR 0.67, 95% CI 0.46–0.98; P ¼ 0.04) (HR 0.79, 95% CI 0.66–0.95; P ¼ 0.01)
Ischaemic stroke No statistical difference Lower rate
(HR 0.95, 95% CI 0.75–1.19; P ¼ 0.65) (HR 0.92, 95% CI 0.74–1.13; P ¼ 0.42)
Myocardial infarction Not available No statistical difference
(HR 0.88, 95% CI 0.66–1.17; P ¼ 0.37)
Death Lower rate Lower rate
(HR 0.65, 95% CI 0.56–0.75; P < 0.00001) (HR 0.89, 95% CI 0.80–0.998; P ¼ 0.047)
Major haemorrhage Lower rate Lower rate
(HR 0.55, 95% CI 0.48–0.63; P < 0.00001) (HR 0.69, 95% CI 0.60–0.80; P < 0.001)
Intracranial haemorrhage Lower rate Lower rate
(HR 0.45, 95% CI 0.31–0.63; P < 0.00001) (HR 0.42, 95% CI 0.30–0.58; P < 0.001)
Gastrointestinal haemorrhage Lower rate No statistical difference
(HR 0.63, 95% CI 0.42–0.95; P ¼ 0.03) (HR 0.89, 95% CI 0.70–1.15; P ¼ 0.37)
ARISTOTLE, Apixaban for reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation.
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some of NOACs such as Apixaban appear to be safer in
terms of gastrointestinal bleeding risk. Nonetheless, there
are some considerations with the use of NOACs.
Importantly, there is limited evidence to support their use
in patients with a severe reduction in kidney function. In
fact, this group of patients were systematically excluded
from RCTs studying the effects of NOACs in comparison to
warfarin. Therefore, the efficacy and safety profile of
these drugs in patients with severe kidney impairment
remains uncertain. A large meta-analysis of cohort studies
showed that among patients with AF and concomitant se-
vere kidney impairment, the use of apixaban was associ-
ated with a lower risk of major bleeding and similar risk of
thromboembolism comparing to warfarin.53 Interestingly,
however, the benefits of warfarin in reducing stroke risk
among these patients have not been established.54,55
Therefore, the comparable thrombo-embolic risk in those
receiving apixaban and warfarin in the previous trial may
be due to the lack of effectiveness of both these drugs.
Another issue is the possibility of use NOACs as an alter-
native to VKAs in patients with valvular heart disease and
prosthetic valve replacement, namely those with biological
and mechanical prosthetic valves (MPV). Mechanical pros-
thetic valves are considered as more thrombogenic than bi-
ological prosthetic valves (BPV), hence the standard
therapeutic option is long-term anticoagulation with VKAs
as NOACs are currently not recommended in patients with
MPV.56
In many analysis, NOACs are considered as alternatives
to VKAs in patients with BPV.56–58 No significant differences
were found between NOACs and VKAs in terms of primary
outcomes including stroke or systemic embolism, all-cause
stroke, ischaemic stroke, myocardial infarction, all-cause
death, and cardiovascular death as well as its safety re-
garding occurrence of bleeding (major bleeding, intracra-
nial haemorrhage, and gastrointestinal haemorrhage).59
That indicates that NOACs, mainly edoxaban and apixaban
are safe and effective also in patients with AF and prior
BPVreplacement or valve repair.60,61
Overall, further studies are needed to understand the
mechanism contributing to thrombo-embolic risk in AF and
kidney impairment.
Conclusions
Randomized controlled trials are the cornerstone for deter-
mining the safety and efficacy of novel treatments while
RWD evaluates the results from the implementation of this
treatment in a broader range of clinical environments.
Both study types are complementary to one another and
Table 5. Edoxaban in comparison to VKA
Dose (mg)
Event
Real-world data studies43 ENGAGE AF-TIMI 48 trial42
Edoxaban 60 mg Edoxaban 30 mg Edoxaban 60/30 mg
Stroke or
systemic
embolism
Lower rate Lower rate No statistical difference
(HR 0.44,
95% CI 0.31–0.64;
P < 0.05)
(HR 0.57,
95% CI 0.42–0.78;
P < 0.05)
(HR 1.13,
95% CI 0.97–1.31;
P ¼ 0.12)
Ischaemic
stroke
No statistical difference44 No statistical difference44 No statistical difference
(HR 0.67,
95% CI 0.36–1.15;
P ¼ 0.18)
(HR 0.73,
95% CI 0.48–1.08;
P ¼ 0.13)
(HR 1.00,
95% CI 0.83–1.19;
P ¼ 0.97)
Myocardial
infarction
Lower rate Lower rate No statistical difference
(HR 0.34,
95% CI 0.15–0.81;
P < 0.05)
(HR 0.58,
95% CI 0.35–0.98;
P < 0.05)
(HR 0.94,
95% CI 0.74–1.19;
P ¼ 0.60)
Death Lower rate Lower rate Lower rate
(HR 0.34,
95% CI 0.15–0.81;
P < 0.05)
(HR 0.55,
95% CI 0.41–0.73;
P < 0.05)
(HR 0.92,
95% CI 0.83–1.01;
P ¼ 0.08)
Major
haemorrhage
Lower rate Lower rate Lower rate
(HR 0.40,
95% CI 0.26–0.61;
P < 0.05)
(HR 0.61,
95% CI 0.43–0.85;
P < 0.05)
(HR 0.80,
95% CI 0.71–0.91;
P < 0.001)
Intracranial
haemorrhage
Lower rate Lower rate Lower rate
(HR 0.35,
95% CI 0.15–0.83;
P < 0.05)
(HR 0.44,
95% CI 0.24–0.82;
P < 0.05)
(HR 0.47,
95% CI 0.34–0.63;
P < 0.001)
Gastrointestinal
haemorrhage
Lower rate Lower rate Higher rate
(HR 0.42,
95% CI 0.26–0.69;
P < 0.05)
(HR 0.59,
95% CI 0.40–0.88;
P < 0.05)
(HR 1.23,
95% CI 1.02–1.50;
P ¼ 0.03)
ENGAGE AF-TIMI 48, The Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis in Myocardial Infarction 48.
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should be used to provide a better understanding of the
management of complex conditions such as AF. By compar-
ing the RCTs and RWD on NOACs, we revealed a significant
agreement between the results that demonstrate the effi-
cacy and safety profile with this group of medications.
Given the broad range of treatment options available for
patients with AF, it is important that as clinicians, we are
able to offer individualized treatment options.
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Erratum to: Practice-derived data on Non-vitamin K antagonist Oral Anticoagulant (NOAC) therapy to complement observations from
randomized trials [European Heart Journal Supplements 2020;22:I1–I12, doi:10.1093/eurheartj/suaa100]
In the originally published version of this manuscript, several errors were noted and listed in this erratum.
Upon the original publication, there was an error under the “Edoxaban vs. warfarin” heading. The text in the first paragraph should read:
“body weight of 60 kg, or the concomitant use of specific PgP inhibitors.” instead of “body weight of 60 kg, or the concomitant use of vera-
pamil or quinidine.”.
Upon the original publication, there were two errors in Table 5, Edoxaban in comparison to VKA. The errors are as follows:
The first column heading under “ENGAGE AF-TIMI 48 trial42” should read: “Edoxaban 60/30 mg” instead of “Edoxaban 60 mg”.
Table 5, included column Edoxaban 30mg” under the heading: “ENGAGE AF-TIMI 48 trial42”. This has been deleted.
These have now been corrected online. The publisher apologises for the errors.
Published on behalf of the European Society of Cardiology. VC The Author(s) 2020.
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